NO20005084L - Heterocyclic glycyl <beta> -alanine derivatives as vitronectin antagonists - Google Patents

Heterocyclic glycyl <beta> -alanine derivatives as vitronectin antagonists

Info

Publication number
NO20005084L
NO20005084L NO20005084A NO20005084A NO20005084L NO 20005084 L NO20005084 L NO 20005084L NO 20005084 A NO20005084 A NO 20005084A NO 20005084 A NO20005084 A NO 20005084A NO 20005084 L NO20005084 L NO 20005084L
Authority
NO
Norway
Prior art keywords
glycyl
heterocyclic
beta
alanine derivatives
vitronectin antagonists
Prior art date
Application number
NO20005084A
Other languages
Norwegian (no)
Other versions
NO20005084D0 (en
Inventor
Nizal Samuel Chandrakumar
Bipinchandra Nanubhai Desai
Balekudru Devadas
Renee Huff
Ish K Khanna
Shashidhar N Rao
Joseph G Rico
Thomas E Rogers
Peter G Ruminski
Mark Andrew Russell
Yi Yu
Alan Frank Gasiecki
James W Malecha
Julie M Miyashiro
Original Assignee
G D Searle & Co Corporate Pate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G D Searle & Co Corporate Pate filed Critical G D Searle & Co Corporate Pate
Publication of NO20005084D0 publication Critical patent/NO20005084D0/en
Publication of NO20005084L publication Critical patent/NO20005084L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NO20005084A 1998-04-10 2000-10-09 Heterocyclic glycyl <beta> -alanine derivatives as vitronectin antagonists NO20005084L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8139498P 1998-04-10 1998-04-10
PCT/US1999/004297 WO1999052896A1 (en) 1998-04-10 1999-04-09 Heterocyclic glycyl beta-alanine derivatives as vitronectin antagonists

Publications (2)

Publication Number Publication Date
NO20005084D0 NO20005084D0 (en) 2000-10-09
NO20005084L true NO20005084L (en) 2000-11-27

Family

ID=22163868

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005084A NO20005084L (en) 1998-04-10 2000-10-09 Heterocyclic glycyl <beta> -alanine derivatives as vitronectin antagonists

Country Status (17)

Country Link
EP (1) EP1070060A1 (en)
JP (1) JP2002511462A (en)
KR (1) KR20010042614A (en)
CN (1) CN1304406A (en)
AR (1) AR015759A1 (en)
AU (1) AU765294B2 (en)
BR (1) BR9910119A (en)
CA (1) CA2326665A1 (en)
CZ (1) CZ20003672A3 (en)
IL (1) IL138677A0 (en)
MY (1) MY133473A (en)
NO (1) NO20005084L (en)
NZ (1) NZ507292A (en)
PL (1) PL343406A1 (en)
RU (1) RU2215746C2 (en)
TW (1) TWI247008B (en)
WO (1) WO1999052896A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
WO2000038665A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co LACTAM INHIBITORS OF FXa AND METHOD
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
WO2000061580A1 (en) 1999-04-12 2000-10-19 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
BR0010092A (en) * 1999-04-28 2002-06-11 Basf Ag Compound, pharmaceutical preparation for oral or parenteral administration, use of a compound, and, use of the pharmaceutical preparation
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003531141A (en) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド Enamine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
AU2001268490A1 (en) 2000-06-15 2001-12-24 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
JP2004505110A (en) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド 3-position substituted isoquinolin-1-yl derivative
DE10204789A1 (en) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitors of the integrin alpha¶v¶beta6
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
CA2510050A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP2205599B1 (en) 2007-10-18 2012-06-06 Boehringer Ingelheim International GmbH Cgrp antagonists
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
US20120149698A1 (en) * 2007-11-22 2012-06-14 Boehringer Ingelheim International Gmbh Nouvel compounds
KR20150038185A (en) 2012-07-18 2015-04-08 세인트 루이스 유니버시티 Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
ES2806276T3 (en) 2015-12-30 2021-02-17 Univ Saint Louis Meta-azacyclic aminobenzoic acid derivatives as pan-integrin antagonists
JP7220653B2 (en) * 2016-11-08 2023-02-10 ブリストル－マイヤーズ スクイブ カンパニー Pyrrolamides as alpha V integrin inhibitors
CN115551846B (en) * 2020-05-14 2024-03-08 Ｕｂｅ株式会社 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (en) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 Pharmaceutical composition for providing treatment for or preventing alport syndrome
CN115626912B (en) * 2022-09-27 2024-03-26 中山大学 Thiourea compound and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
KR100481285B1 (en) * 1995-08-30 2005-08-08 지.디. 썰 엘엘씨 Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivativesas integrin antagonists
DE19629816A1 (en) * 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
EP0934305A4 (en) * 1996-08-29 2001-04-11 Merck & Co Inc Integrin antagonists

Also Published As

Publication number Publication date
BR9910119A (en) 2001-10-09
PL343406A1 (en) 2001-08-13
CN1304406A (en) 2001-07-18
NZ507292A (en) 2003-12-19
KR20010042614A (en) 2001-05-25
AU765294B2 (en) 2003-09-11
JP2002511462A (en) 2002-04-16
MY133473A (en) 2007-11-30
AR015759A1 (en) 2001-05-16
TWI247008B (en) 2006-01-11
NO20005084D0 (en) 2000-10-09
WO1999052896A1 (en) 1999-10-21
RU2215746C2 (en) 2003-11-10
AU3449999A (en) 1999-11-01
CA2326665A1 (en) 1999-10-21
IL138677A0 (en) 2001-10-31
EP1070060A1 (en) 2001-01-24
CZ20003672A3 (en) 2001-08-15

Similar Documents

Publication Publication Date Title
NO20005084L (en) Heterocyclic glycyl &lt;beta&gt; -alanine derivatives as vitronectin antagonists
NO20013559L (en) Aromatic heterocyclic compounds as anti-inflammatory agents
NO20000885L (en) 4-Phenyl-pyridine derivatives
ATE263748T1 (en) ADMANTANE DERIVATIVES
NO20021459L (en) Piperazine derivatives as 5-HT1B antagonists
ATE293104T1 (en) THIAZOLYLAMIDE DERIVATIVES
DK1097127T3 (en) Diacylhydrazine derivatives as integrin inhibitors
EE200100613A (en) 13-methylerythromycin derivatives
DK1187814T3 (en) 5-phenyl-pyrimidine derivatives
DK1202953T3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
PT1237857E (en) NEW FENALQUILOXY-PHENYL DERIVATIVES
ATE257148T1 (en) PROPARGYLETHER DERIVATIVES
ATE273272T1 (en) MEVINOLINE DERIVATIVES
ATE374747T1 (en) MONOFLUORALKYL DERIVATIVES
NO20021251D0 (en) Tienoisoxazolyl- and thienylpyrrazolyl-phenoxy-substituted propyl derivatives useful as D4 antagonists
DK1218340T3 (en) 4-hydroxybiphenylhydrazid derivatives
ATE293592T1 (en) RESOCINE DERIVATIVES
DK1187815T3 (en) 4-phenyl-pyrimidine derivatives
NO20023001D0 (en) Substituted piperazine derivatives as MTP inhibitors
TR200002831A3 (en) Quinolin-4-Il derivatives I
DE60025348D1 (en) Ethanesulfonyl-PIPERIDINE DERIVATIVES
DK1178984T3 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives
NO20022682L (en) Heterocyclic derivatives
ATE269328T1 (en) 1-CYCLOALKYLPYRAZOLYL-BENZOYL DERIVATIVES
NO20021249L (en) Tienoisoxazolphenoxy substituted ethyl and propyl derivatives useful as D4 antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application